Filing Flows › Tango Therapeutics (TNGX) › Q2 2025
Tango Therapeutics (TNGX) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 5, 2025
Tango Therapeutics (TNGX) reported revenue of $3.2M for the second quarter 2025 (Q2 2025), -84% from a year earlier and -41% from the quarter before.
Tango Therapeutics, Q2 2025: revenue $3.2M (-84% year over year), net loss $38.9M, operating cash flow −$36.5M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $3.2M | -41% | -84% |
| Operating profit | −$41.0M | — | — |
| Net earnings | −$38.9M | — | — |
| Operating cash flow | −$36.5M | — | — |
What changed
Revenue was $3.2M in Q2 2025, down 84% year over year and down 41% from the previous quarter.
Operating costs exceeded revenue by $41.0M, an operating margin of -1287.9%. Total costs fell 11% while revenue fell 84%. The quarter ended with a net loss of $38.9M, narrower than the previous quarter's $39.9M loss.
Operating cash flow was −$36.5M. Non-cash charges added back $625K of depreciation and $6.6M of share-based compensation. Working capital and other items used $4.9M. Capital expenditures of $624K exceeded it, leaving free cash flow of −$37.1M.
Questions
What was Tango Therapeutics' revenue in the second quarter 2025?
Tango Therapeutics (TNGX) reported revenue of $3.2M for the second quarter 2025 (Q2 2025), -84% from a year earlier and -41% from the quarter before.
Source: Tango Therapeutics 10-Q on SEC EDGAR.